Nomura Asset Management Co. Ltd. Decreases Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Nomura Asset Management Co. Ltd. lessened its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 27.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 201,503 shares of the medical research company's stock after selling 75,957 shares during the quarter. Nomura Asset Management Co. Ltd.'s holdings in Edwards Lifesciences were worth $13,297,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. FSA Wealth Management LLC bought a new position in Edwards Lifesciences during the third quarter worth about $30,000. Prospera Private Wealth LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $32,000. Avior Wealth Management LLC boosted its holdings in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock worth $35,000 after buying an additional 308 shares during the period. Peoples Bank KS purchased a new position in Edwards Lifesciences in the 3rd quarter valued at approximately $40,000. Finally, JFS Wealth Advisors LLC raised its holdings in Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after acquiring an additional 166 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Up 0.2 %

NYSE:EW traded up $0.16 during trading hours on Thursday, reaching $73.97. The company's stock had a trading volume of 3,852,269 shares, compared to its average volume of 4,649,521. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $43.63 billion, a price-to-earnings ratio of 10.65, a PEG ratio of 3.52 and a beta of 1.12. The firm has a 50-day simple moving average of $69.09 and a 200-day simple moving average of $74.19. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company's revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the firm earned $0.59 earnings per share. Research analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,262,521.36. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the company's stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares of the company's stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,000 shares of company stock worth $2,323,150. 1.27% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on EW shares. UBS Group cut their price target on Edwards Lifesciences from $90.00 to $75.00 and set a "neutral" rating for the company in a report on Tuesday, September 10th. Royal Bank of Canada lifted their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the company an "outperform" rating in a report on Thursday, December 5th. Citigroup upped their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a "buy" rating in a research report on Wednesday. Truist Financial restated a "hold" rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Finally, Canaccord Genuity Group upped their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a "hold" rating in a report on Thursday, December 5th. Seventeen analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $78.65.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.